Khosla Ventures $28 million investment in Rocket Lab is now worth about $1.7 billion

Investing News

In this article

The company rings the Nasdaq bell from its headquarters on Aug. 25, 2021.
Rocket Lab

Khosla Ventures, the Silicon Valley venture capital firm founded by Indian-American billionaire Vinod Khosla, made multiple early bets on Rocket Lab that are paying off enormously now that the space company is public.

The VC firm invested $28.2 million across several Rocket Lab funding rounds between 2013 and 2020, according to a disclosure with the Securities and Exchange Commission, and Khosla now holds just over 115 million shares of Rocket Lab’s common stock.

At Rocket Lab’s closing price of $14.50 a share on Tuesday, the Khosla stake is worth $1.67 billion.

Rocket Lab’s stock is up more than 40% since the company closed its SPAC merger and debuted on the Nasdaq on Aug. 25. The company’s shares rose as much as 6% in trading Wednesday, on track for its fifth consecutive day of gains.

Khosla is poised to benefit even more if Rocket Lab’s stock continues to climb: A clause in its Rocket Lab investment entitles Khosla to an addition 9.3 million shares if the stock’s closing price is at or above $20 a share for at least 20 days between Nov. 23 and Feb. 21.

The venture capital firm is among a number of investors benefiting from a flurry of space companies going public this year. Six space companies have closed SPAC deals so far in 2021 – Rocket Lab, AST & ScienceAstraSpire GlobalMomentus, and Redwire – and several more are expected to go public by year-end, with deals in progress by BlackSkySatellogic and Planet. The first space company in this latest generation to go public through a SPAC was Virgin Galactic, and founder Sir Richard Branson has benefited by selling more than $950 million of the company’s stock in sales.

Become a smarter investor with CNBC Pro.
Get stock picks, analyst calls, exclusive interviews and access to CNBC TV. 
Sign up to start a free trial today.

Articles You May Like

It’s time now to focus on Nvidia, Treasury bonds and a bullish finish to 2024
Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits
Stock-market investors cheered end of election uncertainty. Policy uncertainty remains.
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy’s playbook
Cathie Wood says her ‘volatile’ ARK Innovation fund shouldn’t be a ‘huge slice of any portfolio’